Sepsis, SIRS, and MODS: What's in a name?

被引:39
作者
Nathens, AB [1 ]
Marshall, JC [1 ]
机构
[1] UNIV TORONTO, TORONTO HOSP, DEPT SURG, TORONTO, ON M5G 2C4, CANADA
关键词
D O I
10.1007/s002689900061
中图分类号
R61 [外科手术学];
学科分类号
摘要
Progress in the care of the critically ill patient with life-threatening infection has been hampered by inconsistent, often confusing terminology. The clinical syndrome of sepsis-familiar to all yet definable by none-describes a highly heterogeneous group of disorders with different causes and differing prognoses. The imminent availability of mediator-directed therapy has created a sense of urgency to develop better methods for delineating discrete clinical syndromes and to modulate the host response, which may bring both benefit and harm, depending on the clinical circumstances. The term systemic inflammatory response syndrome (SIRS) nas introduced several gears ago to describe the familiar clinical syndrome of sepsis, independent of its cause, SIRS can result from trauma, pancreatitis, drug reactions, autoimmune disease, and a host of other disorders; when it arises in response to infection, sepsis is said to be present. SIPS describes a dynamic process that has adaptive survival value for the host. The maladaptive consequence of this process in the critically ill patient is the development of progressive hut potentially reversible remote organ dysfunction-the multiple organ dysfunction syndrome, The development of cogent conceptual frameworks for classification of the septic response in critically ill patients is more than a question of linguistic pedantry, Optimal therapy presupposes identification of an homogeneous patient population with a characteristic disease process and a predictable response to an intervention. Although progress has been made in identifying such groups of critically ill patients, the disappointing results of clinical trials of agents that so clearly demonstrate efficacy in animal models indicates that considerable work remains.
引用
收藏
页码:386 / 391
页数:6
相关论文
共 46 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] TREATMENT WITH RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR-ALPHA PROTECTS RATS AGAINST THE LETHALITY, HYPOTENSION, AND HYPOTHERMIA OF GRAM-NEGATIVE SEPSIS
    ALEXANDER, HR
    SHEPPARD, BC
    JENSEN, JC
    LANGSTEIN, HN
    BURESH, CM
    VENZON, D
    WALKER, EC
    FRAKER, DL
    STOVROFF, MC
    NORTON, JA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) : 34 - 39
  • [3] BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779
  • [4] BERNARD GR, IN PRESS AM J RESPIR
  • [5] PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN
    BEUTLER, B
    MILSARK, IW
    CERAMI, AC
    [J]. SCIENCE, 1985, 229 (4716) : 869 - 871
  • [6] Experimental shock - The cause of the low blood pressure produced by muscle injury
    Blalock, A
    [J]. ARCHIVES OF SURGERY, 1930, 20 : 959 - 996
  • [7] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    ABRAMS, JH
    BERNARD, GR
    BIONDI, JW
    CALVIN, JE
    DEMLING, R
    FAHEY, PJ
    FISHER, CJ
    FRANKLIN, C
    GORELICK, KJ
    KELLEY, MA
    MAKI, DG
    MARSHALL, JC
    MERRILL, WW
    PRIBBLE, JP
    RACKOW, EC
    RODELL, TC
    SHEAGREN, JN
    SILVER, M
    SPRUNG, CL
    STRAUBE, RC
    TOBIN, MJ
    TRENHOLME, GM
    WAGNER, DP
    WEBB, CD
    WHERRY, JC
    WIEDEMANN, HP
    WORTEL, CH
    [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874
  • [8] A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) : 653 - 658
  • [9] SEPSIS SYNDROME - A VALID CLINICAL ENTITY
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. CRITICAL CARE MEDICINE, 1989, 17 (05) : 389 - 393